Dr. Reddy’s Labs Q2 PAT seen up 32% YoY to Rs. 380 cr: HDFC Securities

HDFC Securities has come out with its second quarter (July-September’ 18) earnings estimates for the Pharmaceuticals sector. The brokerage house expects Dr. Reddy’s Labs to report net profit at Rs. 380 crore up 32% year-on-year (down 17.6% quarter-on-quarter).

Net Sales are expected to increase by 10.8 percent Y-o-Y (up 5.6 percent Q-o-Q) to Rs. 3,930 crore, according to HDFC Securities.

Earnings before interest, tax, depreciation and amortisation (EBITDA) are likely to rise by 11.5 percent Y-o-Y (down 2.4 percent Q-o-Q) to Rs. 740 crore.

Disclaimer: The views and investment tips expressed by investment experts on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.